Rapport Therapeutics, Inc. · NASDAQ:RAPP
Rapport Therapeutics — American Academy of Neurology Annual Meeting 2026
13 slides from Rapport Therapeutics's conference presentation, Apr 21, 2026
Slide 1: Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of γ8 TARP
Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of γ8 TARP: Impact on RNS Long Episodes and Clinical Seizures William W. Motley, MD, DPhil; Imran H. Quraishi, MD, PhD; Neal M. Nolan, MD; Daniel Friedman, MD; Patrick Landazuri, MD; Vikram R. Rao, MD; Kat
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “
Slide 3: RAP-219 Target, TARPγ8, is Selectively Expressed in Brain Regions Where Focal Onset Seizures Originate
RAP-219 Target, TARPγ8, is Selectively Expressed in Brain Regions Where Focal Onset Seizures Originate RAP-219 is a NAM of AMPA Receptors (AMPARs) TARPγ8 Clinical PETa Bound by TARPγ8 Pre-synaptic Post-synaptic High expression in neuron neuron the neocortex and MTL, where nearly all focal onset seiz
Slide 4: Phase 2a Trial in Patients With Drug-Resistant Focal Onset Seizures
Phase 2a Trial in Patients With Drug-Resistant Focal Onset Seizures New Data 8-Week Open-Label 8-week 12-Week Pretreatment Period Treatment Period Follow-Up Period 4-Week 8-Week Prospective 0.75 mg × 5 days, then 1.25 mg QD RAP-219 Washout Retrospective Baseline Baseline Clinical Seizure Start of En
Slide 5: Patient Disposition and Analysis Populations
Patient Disposition and Analysis Populations 38 Assessed for Eligibility 8 Excluded • Did not meet eligibility criteria 30 Dosed with RAP-219 4 Discontinued Treatment • Adverse event (n=3) • Other (n=1) 26 Completed Treatment Period Analysis Populations → Safety population (N=30) → mITT population f
Slide 6: Patient Demographic and Baseline Characteristics
Patient Demographic and Baseline Characteristics Highly Drug-Resistant FOS Patients are Representative of Those in Registrational Trials Safety Population N=30 Age, years, mean (SD) 40.1 (10.4) Age at first seizure, years, mean (SD) 15.8 (9.3) Sex, male, n (%) 18 (60) Years since RNS implantation, m
Slide 7: Primary Endpoints Achieved With High Statistical Significance
Primary Endpoints Achieved With High Statistical Significance 71% Reduction in LEs; 85.2% Responder Rate (≥30% LE Reduction) Percent Change Responder Analysis Weeks 1–8, N=27 48 LEs at baseline (median, per 28 days); 92% electrographic seizure / LE concordanced aMedian percent change statistical com
Slide 8: Clinical Seizure Secondary Endpoints Achieved with Statistical Significance
Clinical Seizure Secondary Endpoints Achieved with Statistical Significance 77.8% Reduction in CSs; 72% Responder Rate (≥50% CS Reduction) Percent Change Responder Analysis Seizure Freedom (Weeks 1–8) Weeks 1–8, N=25 10 clinical seizures at baseline (median, per 28 days) a Statistical comparison for
Slide 9: Observed RAP-219 Mean Plasma Concentrations
Observed RAP-219 Mean Plasma Concentrations 22-Day Half-Life Results in Concentrations Above Target 50% RO Throughout Follow-Up Treatment Perioda Follow-Up Period aRAP-219 0.75 mg/day for 5 days, followed by RAP-219 1.25 mg/day for the remainder of the 8-week treatment period. 9
Slide 10: Effect of RAP-219 on Long Episodes in Follow-Up Period
Effect of RAP-219 on Long Episodes in Follow-Up Period Significant and Durable LE Reduction Throughout Follow-Up, Consistent With Sustained RAP-219 Exposures Treatment Period Follow-Up Period Median percent change statistical comparisons used the Wilcoxon signed-rank test to determine if the median
Slide 11: Effect of RAP-219 on Clinical Seizures in Follow-Up Period
Effect of RAP-219 on Clinical Seizures in Follow-Up Period Clinically Meaningful Reduction in CSs Throughout Treatment and Follow-Up Treatment Period Follow-Up Period Median percent change statistical comparisons used the Wilcoxon signed-rank test to determine if the median percentage change in CS f
Slide 12: RAP-219 was Generally Well Tolerated
RAP-219 was Generally Well Tolerated 10% Discontinuation Rate Due to TEAEs Treatment Period Follow-Up Period Safety Population Weeks 1–8 (N=30) Weeks 9–16 (N=30) Any TEAE, n (%) 25 (83.3) 10 (33.3) TEAE related to study drug 23 (76.7) 2 (6.7) TEAEs by grade Grade 1 TEAE (mild) 15 (50.0) 7 (23.3) Gra
Slide 13: RAP-219 Progressing into Phase 3 FOS Registrational Trials
RAP-219 Progressing into Phase 3 FOS Registrational Trials Emerging Best-in-Class Profile, if Approved Advancing RAP-219 Development on Strong Phase 2 Data: Potential for Generally Well Tolerated • Initiating two global, multi-center, placebo- Best-in-Class Efficacy controlled Phase 3 clinical trial
Rapport Therapeutics — American Academy of Neurology Annual Meeting 2026 on 6ix